ClinicalTrials.gg
CompletedNCT04796896Updated Jun 13, 2025Results posted

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

A Phase 2/3 interventional study of mRNA-1273 and Placebo in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 91 sites in 2 countries. Open to participants aged 6 Months to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-13.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
11,942
Allocation
Randomized
Ages
6 Months to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Enrollment
4th of 36
11,942 · median 499
Started
2021
with 20 others
Phase 2/3
4 of 36
none open now
Registered
9th of 36
by date
Lead sponsor
11 of 36
ModernaTX, Inc.

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 4th largest by enrollment, is one of 21 that started in 2021, is one of 4 in phase 2/3, and was the 9th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 6 Months to 11 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an optional booster dose (BD) (in Parts 1 and 2).

Read the detailed description

This is a Phase 2/3, 3-part, open-label, dose-escalation, age de-escalation, randomized, observer-blind, placebo-controlled, expansion study intended to infer the effectiveness of mRNA-1273 in children aged 6 months to less than 12 years.

Please access http://www.kidcovestudy.com for additional information, such as Study Overview, Participation, Site Locations along with contact numbers for each location for the study.

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • mRNA-1273
  • mRNA-1273 vaccine
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 11,942 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Months to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • For participants with chronic diseases (such as, asthma, diabetes mellitus, cystic fibrosis, [HIV] infection), the disease should be stable, per investigator assessment.
  • Investigator assessment that the parent(s)/legally acceptable representatives understand and are willing and physically able to comply with protocol mandated follow-up, including all procedures, written is provided, and participants provide assent.
  • For children 2 years of age or older has a at or above the third percentile according to World Health Organization (WHO) Child Growth Standards at the Screening Visit.
  • For children 6 months to \<12 months of age: born at full-term with a minimum birth weight of 2.5 kilograms (kg).
  • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection, agreement to continue adequate contraception or abstinence through 3 months following the second injection (Day 29) and the third dose in Part 3 (Day 149/booster dose Day 1), and not currently breastfeeding.

Key Exclusion Criteria:

  • Known history of SARS-CoV-2 infection within 2 weeks prior to administration of vaccine or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID-19 within 2 weeks prior to administration of vaccine.
  • Prior administration of an or approved CoV (such as, SARS-CoV-2, SARS CoV, Middle East Respiratory Syndrome CoV) vaccine.
  • Treatment with investigational or approved agents for prophylaxis against COVID 19 (such as, receipt of SARS-CoV-2 monoclonal antibodies) within 6 months prior to enrollment.
  • Known to a component of the vaccine or its .
  • A medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results.
  • History of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
  • Received any non-study vaccine within 14 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine)
  • Received intravenous or subcutaneous blood products (red blood cells, , immunoglobulins) within 3 months prior to Day 1
  • Participated in an interventional clinical study within 28 days prior to Day 0 or plans to donate blood products while participating in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11,942 participants (actual)

Study arms

  • Experimental
    mRNA-1273

    Part 1: Participants will receive 2 IM injections of mRNA-1273 at doses pre-specified for this study, on Days 1 and 29. Participants will be offered an optional BD of mRNA-1273 lower than the dose chosen for primary series, ≥6 months after Dose 2. After protocol amendment (PA) 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214. Part 2: Participants will receive 2 IM injections of mRNA-1273 at dose selected from Part 1 on Days 1 and 29. Participants (6 to \<12 year) will be offered an optional BD of mRNA-1273 lower than the dose chosen for primary series, ≥6 months after Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214. Part 3: Participants will receive 2 IM injections of mRNA-1273 on Days 1 and 29 as primary series then 1 IM injection as Dose 3, on Day 149 ≥3 months and ≤5 months after receipt of Dose 2 of primary series. All 3 injections will be administered at lower dose than that of Part 1.

    Biological: mRNA-1273 · Biological: mRNA-1273.214

  • Placebo comparator
    Placebo

    Part 2 only: Participants will receive 2 IM injections of mRNA-1273-matching placebo on Day 1 and Day 29. Participants (6 to \<12 year old) will be offered an optional BD of mRNA-1273 at a dose lower than the dose that was chosen for the primary series for this age group, at least 6 months post-cross-over Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.

    Biological: mRNA-1273 · Biological: Placebo · Biological: mRNA-1273.214

Interventions

  • BiologicalmRNA-1273

    Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

  • BiologicalmRNA-1273.214

    Sterile liquid for injection

07

What researchers measure

Primary outcomes

  1. Parts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: 7 days post-vaccination

  2. Parts 1, 2, and 3: Number of Participants With Unsolicited AEs

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. COVID-19/SARS-CoV-2 infections were considered clinical events for efficacy and not AEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section and presented by each dose group separately.

    Time frame: Up to 28 days post-vaccination

  3. Parts 1, 2, and 3: Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Discontinuation From Study

    An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. AESIs for mRNA-1273 were identified based upon medical concepts that may be related to COVID-19 or were of interest in COVID-19 vaccine safety surveillance. An MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments and visits to healthcare practitioners external to the study site. COVID-19/SARS-CoV-2 infections were considered clinical events for efficacy and not AEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section and presented by each dose group separately.

    Time frame: Up to 2 years

  4. Parts 1 and 2: Geometric Mean (GM) Value of Serum Pseudovirus Neutralizing Antibody ID50 Titers From Study mRNA-1273-P204 (P204) Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years) Vaccine Recipients (Day 57) in Study P301

    Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ and values greater than upper limit of quantification (ULOQ) were replaced by ULOQ if actual values were not available. LLOQ was 18.5 arbitrary units (AU)/milliliter (mL) and ULOQ was 45118 AU/mL for ID50 titer. Per-Protocol (PP) Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative reverse transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2 and negative serology test based on binding antibody (bAb) specific to SARS-CoV-2 nucleocapsid protein at baseline, not receiving highly active antiretroviral therapy (HAART) for participants with HIV; and had no major protocol deviations that impacted key or critical data.

    Time frame: Day 57 P204/Day 57 P301

  5. Parts 2 and 3: GM Concentration of Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key/critical data. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.

    Time frame: Day 57 P204/Day 57 P301

  6. Parts 1 and 2: Seroresponse Rate (SRR) For Serum Pseudovirus Neutralizing Antibody ID50 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Percentage of participants with seroresponse for pseudovirus neutralizing antibody ID50 are reported. Seroresponse: change from below LLOQ to equal above 4\*LLOQ, or at least a 4-fold rise if baseline is ≥LLOQ. LLOQ=18.5 AU/mL and ULOQ=45118 AU/mL for ID50 titer. PP Immunogenicity Subset: all enrolled participants who received planned doses of study vaccine, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 at baseline, not receiving HAART; and had no major protocol deviations that impacted key/critical data. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.

    Time frame: Day 57 P204/Day 57 P301

  7. Parts 2 and 3: SRR For Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 and ULOQ AU/mL was 111433 AU/mL. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.

    Time frame: Day 57 P204/Day 57 P301

  8. Parts 1 and 2: GM Concentration of Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years of Age) Vaccine Recipients in Study P301

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.

    Time frame: BD-Day 29 P204/Day 57 P301

  9. Part 3: GM Concentration of Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.

    Time frame: Third Dose-Day 29 P204/Day 57 P301

  10. Parts 1 and 2: SRR for Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301

    Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.

    Time frame: BD-Day 29 P204/Day 57 P301

  11. Part 3: SRR for Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301

    Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV were not receiving HAART, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.

    Time frame: Third Dose-Day 29 P204/Day 57 P301

Secondary outcomes

  1. Parts 1 and 2: GM Level of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) S Protein-specific Binding Antibody (bAb), as Measured by MesoScale Discovery (MSD) Electrochemiluminescence (ECL) Multiplex Assay on Days 1 and 57

    GM level of SARSCOV2S2P immunoglobulin G (IgG) antibody VAC123/VAC72, as measured by ECL multiplex assay specific to SARS-CoV-2 spike protein is reported. Antibody values reported as \<LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 23 AU/mL and ULOQ was 14000000 AU/mL for VAC72. LLOQ was 69 AU/mL and ULOQ was 14400000 AU/mL for VAC123. PP Immunogenicity Subset: all enrolled participants who received planned doses of study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 protein at baseline, not receiving HAART in participants with HIV; and had no major protocol deviations.

    Time frame: Day 1, Day 57 (1 month after Dose 2)

  2. Parts 1 and 2: GM Level of SARS-CoV-2 S Protein-specific bAb, as Measured by MSD ECL Multiplex Assay on Baseline (Pre-dose 1), Day 57, Day 209, BD-Day 1, and BD-Day 29

    GM level of SARSCOV2S2P IgG antibody VAC123/VAC72 is reported. Antibody values reported as \<LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 23 and ULOQ was 14000000 AU/mL for VAC72. LLOQ was 69 and ULOQ was 14400000 AU/mL for VAC123. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, , not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline, had BD-Day 29 antibody assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not receive off-study COVID-19 vaccination prior to BD-Day 29 visit.

    Time frame: Baseline (Pre-dose 1), Day 57, Day 209, BD-Day 1 (Pre-booster), BD-Day 29 (1 month after booster dose)

  3. Part 3: GM Level of SARS-CoV-2 S Protein-specific bAb, as Measured by MSD ECL Multiplex Assay on Baseline (Pre-dose 1), Day 57, Third Dose-Day 1, Third Dose-Day 29, Third Dose-Day 181

    GM level of SARSCOV2S2P IgG antibody against B.1.1.529 strain is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 102 and ULOQ was 1180000 AU/mL for VAC123. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, participants with HIV were not receiving HAART, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impact key or critical data, and had not receive off-study COVID-19 vaccination prior to BD-Day 29 visit.

    Time frame: Baseline (Pre-dose 1), Day 57, Third Dose-Day 1, Third Dose-Day 29, Third Dose-Day 181

  4. Parts 1 and 2: GM Value of SARS-CoV-2-specific Neutralizing Antibody ID50 Titers on Day 1 and Day 57

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ and values greater than ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.

    Time frame: Day 1 and Day 57 (1 month after Dose 2)

  5. Parts 2 and 3: GM Concentration of SARS-CoV-2-specific Neutralizing Antibody VAC62 on Day 1 and Day 57

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. Data are reported per Baseline SARS-CoV-2 status: Negative and Positive. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.

    Time frame: Day 1 and Day 57 (1 month after Dose 2)

  6. Parts 1 and 2: GM Concentration of Post-booster SARS-CoV-2-specific Neutralizing Antibody VAC62 on Baseline, Day 57, Day 209, BD-Day 1, and BD-Day 29

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.

    Time frame: Baseline (Pre-Dose 1), Day 57 (1 month after Dose 2), Day 209 (6 months after Dose 2), BD-Day 1 (Pre-booster), and BD-Day 29 (1 month after booster dose or third dose)

  7. Part 3: GM Concentration of Post-third Dose SARS-CoV-2-specific Neutralizing Antibody VAC62 on Baseline, Day 57, Third Dose-Day 1, Third Dose-Day 29, and Third Dose-Day 181

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.

    Time frame: Baseline (Pre-Dose 1), Day 57 (1 month after Dose 2), Third Dose-Day 1 (at least 3 months or 6 months after Dose 2), Third Dose-Day 29 (1 month after third dose), and Third Dose-Day 181 (6 months after third dose)

  8. Part 2: Number of Participants With SARS-CoV-2 Infection Including Symptomatic and Asymptomatic Infection (by Serology and/or RT-PCR)

    SARS-CoV-2 infection was defined in participants with negative SARS-CoV-2 at baseline: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1, that became positive (as measured by Roche Elecsys) postbaseline; OR positive RT-PCR postbaseline. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.

    Time frame: 14 days after second injection

  9. Part 2: Number of Participants With Asymptomatic SARS-CoV-2 Infection, Measured by RT-PCR and/or bAb Levels Against SARS-CoV-2 Nucleocapsid Protein (by Roche Elecsys)

    Asymptomatic SARS-CoV-2 infection was identified by absence of symptoms and infections as detected by RT-PCR or serology tests: Absence of COVID-19 symptoms AND at least 1 from following: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1 that became positive post-baseline, OR positive RT-PCR test post-baseline. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.

    Time frame: 14 days after second injection

  10. Part 2: Number of Participants With Occurrence of COVID-19 (Per US Centers for Disease Control and Prevention [CDC] Case Definition of COVID-19)

    A COVID-19 case was identified as a positive post-baseline RT-PCR test result together with at least 1 of following systemic symptoms: fever (≥ 38 degrees Celsius \[°C\]/≥ 100.4 degree Fahrenheit \[°F\]) or chills, fatigue, headache, myalgia, nasal congestion or rhinorrhea, new loss of taste or smell, sore throat, abdominal pain, diarrhoea, nausea/vomiting, poor appetite/poor feeding; or at least 1 of following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.

    Time frame: 14 days after second injection

Other outcomes

  1. Number of Deaths Related to Study Drug

    A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

    Time frame: Up to 2 years

08

Results

Posted Jun 13, 2025

Participant flow

The study was conducted in 3 parts: Part 1 (open-label; dose-escalation and age de-escalation), Part 2 (placebo-controlled), and Part 3 (open-label; lower dose regimen).

Participant flow — Overall Study
MilestonePart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µg
Started380371751491501004301110083040669199590
Received first injection38037175149150997300510073031667199390
Received second injection3793717514915097429959843007649197984
Received first injection in open-label000007020640044400
Received booster dose230249409912546920022821301237101670
Received crossover vaccination000007020640044400
Completed3073165513110555623295152086366138751
Not completed735520184544868249395430360839
Withdrew: Adverse event100001101110
Withdrew: Lost to follow-up2415642155237522214314218
Withdrew: Received emergency use authorization (eua) vaccine54031194372222911591
Withdrew: Physician decision1000031817050
Withdrew: Withdrawal by subject3631118161622991493039419216
Withdrew: Other than specified65326318666388482584
Withdrew: Protocol deviation000112222100
Withdrew: Missing000000212110
Withdrew: Death000000001000

Outcome measures

PrimaryParts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
7 days post-vaccination
Reported as:
Count of participants · Participants
Parts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsPart 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μgPart 1 (6-11 Years): PS mRNA-1273 100 μg - BD 25 μgPart 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 50 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 25 μg - BD 25 μgPart 1 (2-5 Years): PS mRNA-1273 50 μg - BD 25 μgPart 2 (6 Months-5 Yrs): PS PBO - mRNA-1273 25 μg - BD 25 μgPart 2 (6 Months-5 Years): PS mRNA-1273 25 μg - BD 25 μgPart 2(6-11 Yrs): PS Placebo - mRNA-1273 50 μg - BD 1273 25 μgPart 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μgPart 3 (6-11 Years): BD mRNA-1273 25 µgPart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): mRNA-1273 25 µg
Parts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)2162219324467364123581726303743676214714182329837972800596188966
PrimaryParts 1, 2, and 3: Number of Participants With Unsolicited AEs

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. COVID-19/SARS-CoV-2 infections were considered clinical events for efficacy and not AEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section and presented by each dose group separately.

Time frame:
Up to 28 days post-vaccination
Reported as:
Count of participants · Participants
Parts 1, 2, and 3: Number of Participants With Unsolicited AEs
ParticipantsPart 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μgPart 1 (6-11 Years): PS mRNA-1273 100 μg - BD 25 μgPart 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 50 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 25 μg - BD 25 μgPart 1 (2-5 Years): PS mRNA-1273 50 μg - BD 25 μgPart 2 (6 Months-5 Yrs): PS PBO - mRNA-1273 25 μg - BD 25 μgPart 2 (6 Months-5 Years): PS mRNA-1273 25 μg - BD 25 μgPart 2(6-11 Yrs): PS Placebo - mRNA-1273 50 μg - BD 1273 25 μgPart 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μgPart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): mRNA-1273 25 µg
Parts 1, 2, and 3: Number of Participants With Unsolicited AEs3820248418153319610692155175785108788317
PrimaryParts 1, 2, and 3: Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Discontinuation From Study

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. AESIs for mRNA-1273 were identified based upon medical concepts that may be related to COVID-19 or were of interest in COVID-19 vaccine safety surveillance. An MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments and visits to healthcare practitioners external to the study site. COVID-19/SARS-CoV-2 infections were considered clinical events for efficacy and not AEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section and presented by each dose group separately.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Parts 1, 2, and 3: Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Discontinuation From Study
ParticipantsPart 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μgPart 1 (6-11 Years): PS mRNA-1273 100 μg - BD 25 μgPart 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 50 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 25 μg - BD 25 μgPart 1 (2-5 Years): PS mRNA-1273 50 μg - BD 25 μgPart 2 (6 Months-5 Yrs): PS PBO - mRNA-1273 25 μg - BD 25 μgPart 2 (6 Months-5 Years): PS mRNA-1273 25 μg - BD 25 μgPart 2(6 M-5 Yr): PS PBO - mRNA-1273 25 μg - BD 1273.214 10 μgPart 2(6 Months-5 Yrs): PS mRNA-1273 25 μg - BD 1273.214 10 μgPart 2(6 M-5 Yr): PS PBO - mRNA-1273 25 μg - BD 1273.214 25 μgPart 2(6 Months-5 Yrs): PS mRNA-1273 25 μg - BD 1273.214 25 μgPart 2(6-11 Yrs): PS Placebo - mRNA-1273 50 μg - BD 1273 25 μgPart 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μgPart 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg - BD 1273.214 25 μgPart 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273.214 25 μgPart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): mRNA-1273 25 µgPart 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg (Crossover)Part 2 (2-5 Years): PS PBO - mRNA-1273 25 μg (Crossover)Part 2 (6-23 Months): PBO - mRNA-1273 25 μg (Crossover)
SAEs111000010716003700530032232451384
AESIs10200000120002900570121913130311
MAAEs8571591623417310182901131376161634175169328010510951687123722221204171
AEs Leading to Discontinuation00000000001000000100000110000
PrimaryParts 1 and 2: Geometric Mean (GM) Value of Serum Pseudovirus Neutralizing Antibody ID50 Titers From Study mRNA-1273-P204 (P204) Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years) Vaccine Recipients (Day 57) in Study P301

Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ and values greater than upper limit of quantification (ULOQ) were replaced by ULOQ if actual values were not available. LLOQ was 18.5 arbitrary units (AU)/milliliter (mL) and ULOQ was 45118 AU/mL for ID50 titer. Per-Protocol (PP) Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative reverse transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2 and negative serology test based on binding antibody (bAb) specific to SARS-CoV-2 nucleocapsid protein at baseline, not receiving highly active antiretroviral therapy (HAART) for participants with HIV; and had no major protocol deviations that impacted key or critical data.

Time frame:
Day 57 P204/Day 57 P301
Reported as:
Geometric mean · titer
Parts 1 and 2: Geometric Mean (GM) Value of Serum Pseudovirus Neutralizing Antibody ID50 Titers From Study mRNA-1273-P204 (P204) Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years) Vaccine Recipients (Day 57) in Study P301
titerPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 2 (6-11 Years): mRNA-1273 50 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg
Parts 1 and 2: Geometric Mean (GM) Value of Serum Pseudovirus Neutralizing Antibody ID50 Titers From Study mRNA-1273-P204 (P204) Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years) Vaccine Recipients (Day 57) in Study P3011012.5 (848.2 to 1208.6)1845.9 (1600.5 to 2128.9)1782.6 (1542.0 to 2060.7)1669.1 (1504.5 to 1851.6)1890.2 (1603.8 to 2227.7)1618.3 (1460.0 to 1793.9)1321.9 (1196.5 to 1460.5)
Statistical analysis
  • Part 2 (6-11 Years): mRNA-1273 50 µg vs Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg · Gmr: 1.224 · 95% CI 1.061 to 1.413
PrimaryParts 2 and 3: GM Concentration of Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key/critical data. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.

Time frame:
Day 57 P204/Day 57 P301
Reported as:
Geometric mean · AU/mL
Parts 2 and 3: GM Concentration of Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
AU/mLPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg
Parts 2 and 3: GM Concentration of Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P3011394.1 (1267.7 to 1533.1)1759.8 (1606.7 to 1927.4)4368.6 (3339.6 to 5714.6)1400.4 (1272.7 to 1541.0)
Statistical analysis
  • Part 2 (2-5 Years): mRNA-1273 25 µg · Gmr: 0.995 · 95% CI 0.870 to 1.139
  • Part 2 (6-23 Months): mRNA-1273 25 µg · Gmr: 1.257 · 95% CI 1.101 to 1.434
PrimaryParts 1 and 2: Seroresponse Rate (SRR) For Serum Pseudovirus Neutralizing Antibody ID50 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Percentage of participants with seroresponse for pseudovirus neutralizing antibody ID50 are reported. Seroresponse: change from below LLOQ to equal above 4\*LLOQ, or at least a 4-fold rise if baseline is ≥LLOQ. LLOQ=18.5 AU/mL and ULOQ=45118 AU/mL for ID50 titer. PP Immunogenicity Subset: all enrolled participants who received planned doses of study vaccine, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 at baseline, not receiving HAART; and had no major protocol deviations that impacted key/critical data. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.

Time frame:
Day 57 P204/Day 57 P301
Reported as:
Number · percentage of participants
Parts 1 and 2: Seroresponse Rate (SRR) For Serum Pseudovirus Neutralizing Antibody ID50 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
percentage of participantsPart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): mRNA-1273 50 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg
Parts 1 and 2: Seroresponse Rate (SRR) For Serum Pseudovirus Neutralizing Antibody ID50 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P30199.5 (97.3 to 99.9)100 (93.6 to 100.0)100 (92.9 to 100)100 (94.7 to 100.0)100 (96.2 to 100.0)99.0 (97.2 to 99.8)99.3 (97.6 to 99.9)
Statistical analysis
  • Part 2 (6-11 Years): mRNA-1273 50 µg · Percentage difference: -0.3 · 95% CI -2.2 to 1.6
PrimaryParts 2 and 3: SRR For Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 and ULOQ AU/mL was 111433 AU/mL. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.

Time frame:
Day 57 P204/Day 57 P301
Reported as:
Number · percentage of participants
Parts 2 and 3: SRR For Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
percentage of participantsPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg
Parts 2 and 3: SRR For Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P30198.9 (96.9 to 99.8)100 (98.6 to 100.0)88.5 (77.8 to 95.3)99.3 (97.6 to 99.9)
Statistical analysis
  • Part 2 (2-5 Years): mRNA-1273 25 µg · Percentage difference: -0.4 · 95% CI -2.5 to 1.5
  • Part 2 (6-23 Months): mRNA-1273 25 µg · Percentage difference: 0.7 · 95% CI -0.8 to 2.4
PrimaryParts 1 and 2: GM Concentration of Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years of Age) Vaccine Recipients in Study P301

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.

Time frame:
BD-Day 29 P204/Day 57 P301
Reported as:
Geometric mean · AU/mL
Parts 1 and 2: GM Concentration of Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years of Age) Vaccine Recipients in Study P301
AU/mLStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μgBD Phase Part 1 (6 Month-5 Yrs): PS mRNA-1273 25 μg - BD 10 μgBD Part 1 and 2 (6-11 Yrs): PS mRNA-1273 50 μg - BD 1273 25 μg
Parts 1 and 2: GM Concentration of Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years of Age) Vaccine Recipients in Study P3011400.4 (1272.7 to 1541.0)5457.2 (4525.7 to 6580.3)5575.9 (5026.8 to 6184.9)
Statistical analysis
  • Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg vs BD Phase Part 1 (6 Month-5 Yrs): PS mRNA-1273 25 μg - BD 10 μg · Gmr: 3.897 · 95% CI 3.158 to 4.808
  • Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg vs BD Part 1 and 2 (6-11 Yrs): PS mRNA-1273 50 μg - BD 1273 25 μg · Gmr: 3.982 · 95% CI 3.404 to 4.657
PrimaryPart 3: GM Concentration of Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.

Time frame:
Third Dose-Day 29 P204/Day 57 P301
Reported as:
Geometric mean · AU/mL
Part 3: GM Concentration of Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301
AU/mLPart 3 (6-11 Years): BD mRNA-1273 25 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg
Part 3: GM Concentration of Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P3014616.6 (3669.4 to 5808.3)1400.4 (1272.7 to 1541.0)
PrimaryParts 1 and 2: SRR for Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301

Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.

Time frame:
BD-Day 29 P204/Day 57 P301
Reported as:
Number · percentage of participants
Parts 1 and 2: SRR for Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301
percentage of participantsStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μgBD Phase Part 1 (6 Month-5 Yrs): PS mRNA-1273 25 μg - BD 10 μgBD Part 1 and 2 (6-11 Yrs): PS mRNA-1273 50 μg - BD 1273 25 μg
Parts 1 and 2: SRR for Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P30199.3 (97.6 to 99.9)100 (95.0 to 100.0)100 (97.2 to 100.0)
Statistical analysis
  • Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg vs BD Phase Part 1 (6 Month-5 Yrs): PS mRNA-1273 25 μg - BD 10 μg · Percentage difference: 0.7 · 95% CI -4.4 to 2.4
  • Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg vs BD Part 1 and 2 (6-11 Yrs): PS mRNA-1273 50 μg - BD 1273 25 μg · Percentage difference: 0.7 · 95% CI -2.2 to 2.4
PrimaryPart 3: SRR for Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301

Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV were not receiving HAART, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.

Time frame:
Third Dose-Day 29 P204/Day 57 P301
Reported as:
Number · percentage of participants
Part 3: SRR for Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301
percentage of participantsPart 3 (6-11 Years): BD mRNA-1273 25 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg
Part 3: SRR for Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P30190.0 (78.2 to 96.7)99.3 (97.6 to 99.9)
SecondaryParts 1 and 2: GM Level of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) S Protein-specific Binding Antibody (bAb), as Measured by MesoScale Discovery (MSD) Electrochemiluminescence (ECL) Multiplex Assay on Days 1 and 57

GM level of SARSCOV2S2P immunoglobulin G (IgG) antibody VAC123/VAC72, as measured by ECL multiplex assay specific to SARS-CoV-2 spike protein is reported. Antibody values reported as \<LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 23 AU/mL and ULOQ was 14000000 AU/mL for VAC72. LLOQ was 69 AU/mL and ULOQ was 14400000 AU/mL for VAC123. PP Immunogenicity Subset: all enrolled participants who received planned doses of study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 protein at baseline, not receiving HAART in participants with HIV; and had no major protocol deviations.

Time frame:
Day 1, Day 57 (1 month after Dose 2)
Reported as:
Geometric mean · AU/mL
Parts 1 and 2: GM Level of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) S Protein-specific Binding Antibody (bAb), as Measured by MesoScale Discovery (MSD) Electrochemiluminescence (ECL) Multiplex Assay on Days 1 and 57
AU/mLPart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): mRNA-1273 25 µg
Baseline (Day 1)35.6 (31.0 to 40.8)49.1 (33.9 to 71.1)15.8 (13.5 to 18.5)33.7 (26.2 to 43.4)14.6 (12.8 to 16.7)32.6 (28.5 to 37.3)24.5 (21.7 to 27.5)22.0 (19.1 to 25.3)
Day 57325784.0 (302917.7 to 350376.4)457349.2 (402424.0 to 519770.8)261952.0 (227935.8 to 301044.7)417419.8 (359399.2 to 484807.0)297561.7 (234740.9 to 377194.3)293118.9 (261748.3 to 328249.4)235059.2 (198610.2 to 278197.3)293955.4 (256077.7 to 337435.8)
SecondaryParts 1 and 2: GM Level of SARS-CoV-2 S Protein-specific bAb, as Measured by MSD ECL Multiplex Assay on Baseline (Pre-dose 1), Day 57, Day 209, BD-Day 1, and BD-Day 29

GM level of SARSCOV2S2P IgG antibody VAC123/VAC72 is reported. Antibody values reported as \<LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 23 and ULOQ was 14000000 AU/mL for VAC72. LLOQ was 69 and ULOQ was 14400000 AU/mL for VAC123. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, , not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline, had BD-Day 29 antibody assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not receive off-study COVID-19 vaccination prior to BD-Day 29 visit.

Time frame:
Baseline (Pre-dose 1), Day 57, Day 209, BD-Day 1 (Pre-booster), BD-Day 29 (1 month after booster dose)
Reported as:
Geometric mean · AU/mL
Parts 1 and 2: GM Level of SARS-CoV-2 S Protein-specific bAb, as Measured by MSD ECL Multiplex Assay on Baseline (Pre-dose 1), Day 57, Day 209, BD-Day 1, and BD-Day 29
AU/mLPart 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μgPart 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μgPart 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μg
Baseline50.0 (42.7 to 58.6)37.5 (34.3 to 40.9)34.5 (NA to NA)51.9 (44.6 to 60.3)
Day 57302128.3 (266991.2 to 341889.7)279427.6 (242953.8 to 321377.2)241874.9 (180565.7 to 324001.0)336189.6 (257789.9 to 438432.5)
Day 20974516.9 (63553.5 to 87371.5)66516.5 (59365.2 to 74529.2)71427.5 (50801.5 to 100427.9)85360.1 (71680.4 to 101650.5)
BD-Day 166677.7 (52382.4 to 84874.2)68322.4 (53860.8 to 86667.0)50621.5 (34112.1 to 75121.2)86416.4 (72836.0 to 102528.9)
BD-Day 29633999.7 (561311.4 to 716101.0)675348.1 (584405.3 to 780443.0)536478.9 (403508.2 to 713268.2)520973.0 (469812.4 to 577704.8)
SecondaryPart 3: GM Level of SARS-CoV-2 S Protein-specific bAb, as Measured by MSD ECL Multiplex Assay on Baseline (Pre-dose 1), Day 57, Third Dose-Day 1, Third Dose-Day 29, Third Dose-Day 181

GM level of SARSCOV2S2P IgG antibody against B.1.1.529 strain is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 102 and ULOQ was 1180000 AU/mL for VAC123. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, participants with HIV were not receiving HAART, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impact key or critical data, and had not receive off-study COVID-19 vaccination prior to BD-Day 29 visit.

Time frame:
Baseline (Pre-dose 1), Day 57, Third Dose-Day 1, Third Dose-Day 29, Third Dose-Day 181
Reported as:
Geometric mean · AU/mL
Part 3: GM Level of SARS-CoV-2 S Protein-specific bAb, as Measured by MSD ECL Multiplex Assay on Baseline (Pre-dose 1), Day 57, Third Dose-Day 1, Third Dose-Day 29, Third Dose-Day 181
AU/mLPart 3 (6-11 Years): BD mRNA-1273 25 µg
Baseline (Pre-dose 1)4659.5 (2918.7 to 7438.5)
Day 57141758.0 (118762.4 to 169206.2)
Third Dose-Day 148176.2 (38955.2 to 59580.0)
Third Dose-Day 2993436.4 (77735.5 to 112308.5)
Third Dose-Day 18140271.7 (32950.9 to 49219.2)
SecondaryParts 1 and 2: GM Value of SARS-CoV-2-specific Neutralizing Antibody ID50 Titers on Day 1 and Day 57

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ and values greater than ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.

Time frame:
Day 1 and Day 57 (1 month after Dose 2)
Reported as:
Geometric mean · titer
Parts 1 and 2: GM Value of SARS-CoV-2-specific Neutralizing Antibody ID50 Titers on Day 1 and Day 57
titerPart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): mRNA-1273 50 µg
Day 19.3 (9.2 to 9.5)9.6 (8.9 to 10.3)9.3 (NA to NA)9.3 (NA to NA)9.6 (9.3 to 9.9)9.3 (NA to NA)
Day 571669.1 (1504.5 to 1851.6)1890.2 (1603.8 to 2227.7)1012.5 (848.2 to 1208.6)1845.9 (1600.5 to 2128.9)1782.6 (1542.0 to 2060.7)1618.3 (1460.0 to 1793.9)
SecondaryParts 2 and 3: GM Concentration of SARS-CoV-2-specific Neutralizing Antibody VAC62 on Day 1 and Day 57

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. Data are reported per Baseline SARS-CoV-2 status: Negative and Positive. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.

Time frame:
Day 1 and Day 57 (1 month after Dose 2)
Reported as:
Geometric mean · AU/mL
Parts 2 and 3: GM Concentration of SARS-CoV-2-specific Neutralizing Antibody VAC62 on Day 1 and Day 57
AU/mLPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µg
Baseline SARS-CoV-2 (Negative): Day 17.9 (7.5 to 8.4)8.0 (7.5 to 8.5)21.5 (2.6 to 175.1)
Baseline SARS-CoV-2 (Positive): Day 1175.3 (130.4 to 235.6)199.9 (109.2 to 365.9)177.5 (111.2 to 283.3)
Baseline SARS-CoV-2(Negative): Day 571398.1 (1271.9 to 1536.8)1760.8 (1609.7 to 1926.0)2140.6 (728.7 to 6288.7)
Baseline SARS-CoV-2 (Positive): Day 577430.0 (5188.4 to 10640.1)10411.6 (6712.1 to 16150.1)4592.9 (3470.7 to 6077.9)
SecondaryParts 1 and 2: GM Concentration of Post-booster SARS-CoV-2-specific Neutralizing Antibody VAC62 on Baseline, Day 57, Day 209, BD-Day 1, and BD-Day 29

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.

Time frame:
Baseline (Pre-Dose 1), Day 57 (1 month after Dose 2), Day 209 (6 months after Dose 2), BD-Day 1 (Pre-booster), and BD-Day 29 (1 month after booster dose or third dose)
Reported as:
Geometric mean · AU/mL
Parts 1 and 2: GM Concentration of Post-booster SARS-CoV-2-specific Neutralizing Antibody VAC62 on Baseline, Day 57, Day 209, BD-Day 1, and BD-Day 29
AU/mLPart 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μgPart 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μgPart 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μgPart 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μg
Baseline9.0 (8.2 to 9.9)12.8 (10.0 to 16.3)7.8 (7.1 to 8.6)9.3 (8.5 to 10.3)
Day 571557.1 (1294.2 to 1873.5)1275.0 (983.0 to 1653.8)1718.7 (1316.5 to 2243.7)1503.3 (1292.3 to 1748.7)
Day 209448.6 (376.9 to 533.8)544.5 (343.1 to 864.0)790.7 (633.8 to 986.4)530.3 (432.5 to 650.2)
BD-Day 1558.0 (408.5 to 762.2)447.2 (270.0 to 740.7)795.5 (640.8 to 987.5)627.9 (467.8 to 842.8)
BD-Day 296474.7 (5406.0 to 7754.8)5778.7 (4039.7 to 8266.4)5805.4 (5122.4 to 6579.4)6991.6 (6091.2 to 8025.0)
SecondaryPart 3: GM Concentration of Post-third Dose SARS-CoV-2-specific Neutralizing Antibody VAC62 on Baseline, Day 57, Third Dose-Day 1, Third Dose-Day 29, and Third Dose-Day 181

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.

Time frame:
Baseline (Pre-Dose 1), Day 57 (1 month after Dose 2), Third Dose-Day 1 (at least 3 months or 6 months after Dose 2), Third Dose-Day 29 (1 month after third dose), and Third Dose-Day 181 (6 months after third dose)
Reported as:
Geometric mean · AU/mL
Part 3: GM Concentration of Post-third Dose SARS-CoV-2-specific Neutralizing Antibody VAC62 on Baseline, Day 57, Third Dose-Day 1, Third Dose-Day 29, and Third Dose-Day 181
AU/mLPart 3 (6-11 Years): BD mRNA-1273 25 µg
Baseline120.0 (71.9 to 200.3)
Day 573775.0 (2767.5 to 5149.3)
Third Dose-Day 11839.1 (1279.8 to 2643.0)
Third Dose-Day 294616.6 (3669.4 to 5808.3)
Third Dose-Day 1811432.5 (1038.6 to 1975.8)
SecondaryPart 2: Number of Participants With SARS-CoV-2 Infection Including Symptomatic and Asymptomatic Infection (by Serology and/or RT-PCR)

SARS-CoV-2 infection was defined in participants with negative SARS-CoV-2 at baseline: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1, that became positive (as measured by Roche Elecsys) postbaseline; OR positive RT-PCR postbaseline. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.

Time frame:
14 days after second injection
Reported as:
Count of participants · Participants
Part 2: Number of Participants With SARS-CoV-2 Infection Including Symptomatic and Asymptomatic Infection (by Serology and/or RT-PCR)
ParticipantsPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µg
Part 2: Number of Participants With SARS-CoV-2 Infection Including Symptomatic and Asymptomatic Infection (by Serology and/or RT-PCR)141317833094198
Statistical analysis
  • Part 2 (6-11 Years): Placebo vs Part 2 (6-11 Years): mRNA-1273 50 µg · Vaccine efficacy: 0.706 · 95% CI 0.325 to 0.873Vaccine efficacy (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
  • Part 2 (2-5 Years): Placebo vs Part 2 (2-5 Years): mRNA-1273 25 µg · Vaccine efficacy: 0.409 · 95% CI 0.287 to 0.509Vaccine Efficacy (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
  • Part 2 (6-23 Months): Placebo vs Part 2 (6-23 Months): mRNA-1273 25 µg · Vaccine efficacy: 0.324 · 95% CI 0.127 to 0.474Vaccine Efficacy (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
SecondaryPart 2: Number of Participants With Asymptomatic SARS-CoV-2 Infection, Measured by RT-PCR and/or bAb Levels Against SARS-CoV-2 Nucleocapsid Protein (by Roche Elecsys)

Asymptomatic SARS-CoV-2 infection was identified by absence of symptoms and infections as detected by RT-PCR or serology tests: Absence of COVID-19 symptoms AND at least 1 from following: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1 that became positive post-baseline, OR positive RT-PCR test post-baseline. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.

Time frame:
14 days after second injection
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Asymptomatic SARS-CoV-2 Infection, Measured by RT-PCR and/or bAb Levels Against SARS-CoV-2 Nucleocapsid Protein (by Roche Elecsys)
ParticipantsPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µg
Part 2: Number of Participants With Asymptomatic SARS-CoV-2 Infection, Measured by RT-PCR and/or bAb Levels Against SARS-CoV-2 Nucleocapsid Protein (by Roche Elecsys)1010551242170
Statistical analysis
  • Part 2 (6-11 Years): Placebo vs Part 2 (6-11 Years): mRNA-1273 50 µg · Vaccine efficacy: 0.683 · 95% CI 0.151 to 0.882Vaccine Efficacy (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
  • Part 2 (2-5 Years): Placebo vs Part 2 (2-5 Years): mRNA-1273 25 µg · Vaccine efficacy: 0.281 · 95% CI -0.007 to 0.480Vaccine Efficacy (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
  • Part 2 (6-23 Months): Placebo vs Part 2 (6-23 Months): mRNA-1273 25 µg · Vaccine efficacy: -0.068 · 95% CI -0.832 to 0.352Vaccine Efficacy (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
SecondaryPart 2: Number of Participants With Occurrence of COVID-19 (Per US Centers for Disease Control and Prevention [CDC] Case Definition of COVID-19)

A COVID-19 case was identified as a positive post-baseline RT-PCR test result together with at least 1 of following systemic symptoms: fever (≥ 38 degrees Celsius \[°C\]/≥ 100.4 degree Fahrenheit \[°F\]) or chills, fatigue, headache, myalgia, nasal congestion or rhinorrhea, new loss of taste or smell, sore throat, abdominal pain, diarrhoea, nausea/vomiting, poor appetite/poor feeding; or at least 1 of following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.

Time frame:
14 days after second injection
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Occurrence of COVID-19 (Per US Centers for Disease Control and Prevention [CDC] Case Definition of COVID-19)
ParticipantsPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µg
Part 2: Number of Participants With Occurrence of COVID-19 (Per US Centers for Disease Control and Prevention [CDC] Case Definition of COVID-19)4312520773130
Statistical analysis
  • Part 2 (6-11 Years): Placebo vs Part 2 (6-11 Years): mRNA-1273 50 µg · Vaccine efficacy: 0.760 · 95% CI -0.416 to 0.965Vaccine Efficacy (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
  • Part 2 (2-5 Years): Placebo vs Part 2 (2-5 Years): mRNA-1273 25 µg · Vaccine efficacy: 0.466 · 95% CI 0.328 to 0.574Vaccine Efficacy (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
  • Part 2 (6-23 Months): Placebo vs Part 2 (6-23 Months): mRNA-1273 25 µg · Vaccine efficacy: 0.432 · 95% CI 0.232 to 0.576Vaccine Efficacy (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
Other pre-specifiedNumber of Deaths Related to Study Drug

A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Deaths Related to Study Drug
ParticipantsPart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µgPart 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg (Crossover)Part 2 (2-5 Years): PS PBO - mRNA-1273 25 μg (Crossover)Part 2 (6-23 Months): PBO - mRNA-1273 25 μg (Crossover)Part 3 (6-11 Years): BD mRNA-1273 25 µg6-11 Years: BD mRNA-1273 25 μg6-11 Yrs: BD mRNA-1273.214 25 μg6 Months-5 Yrs: BD mRNA-1273 10 μg6 Months-5 Yrs: BD mRNA-1273 25 μg6 Months-5 Yrs: BD mRNA-1273.214 10 μg6 Months-5 Yrs: BD mRNA-1273.214 25 μg
Deaths0000000000000000000010
Deaths related to study drug0000000000000000000000

Adverse events

Collected over Up to 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 (6-11 Years): mRNA-1273 50 µg0/380 (0%)5/380 (1.3%)145/380 (38.2%)
Part 1 (6-11 Years): mRNA-1273 100 µg0/371 (0%)3/371 (0.8%)134/371 (36.1%)
Part 1 (2-5 Years): mRNA-1273 25 µg0/69 (0%)0/69 (0%)30/69 (43.5%)
Part 1 (2-5 Years): mRNA-1273 50 µg0/155 (0%)0/155 (0%)78/155 (50.3%)
Part 1 (6-23 Months): mRNA-1273 25 µg0/150 (0%)3/150 (2%)111/150 (74%)
Part 2 (6-11 Years): Placebo0/995 (0%)1/995 (0.1%)100/995 (10.1%)
Part 2 (6-11 Years): mRNA-1273 50 µg0/3,007 (0%)22/3,007 (0.7%)573/3,007 (19.1%)
Part 2 (2-5 Years): Placebo0/1,007 (0%)3/1,007 (0.3%)356/1,007 (35.4%)
Part 2 (2-5 Years): mRNA-1273 25 µg0/3,031 (0%)32/3,031 (1.1%)1,341/3,031 (44.2%)
Part 2 (6-23 Months): Placebo0/666 (0%)7/666 (1.1%)317/666 (47.6%)
Part 2 (6-23 Months): mRNA-1273 25 µg0/1,994 (0%)45/1,994 (2.3%)1,095/1,994 (54.9%)
Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg0/90 (0%)1/90 (1.1%)9/90 (10%)
Part 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg (Crossover)0/701 (0%)3/701 (0.4%)64/701 (9.1%)
Part 2 (2-5 Years): PS PBO - mRNA-1273 25 μg (Crossover)0/640 (0%)8/640 (1.3%)58/640 (9.1%)
Part 2 (6-23 Months): PBO - mRNA-1273 25 μg (Crossover)0/444 (0%)4/444 (0.9%)62/444 (14%)
Part 3 (6-11 Years): BD mRNA-1273 25 µg0/70 (0%)0/70 (0%)4/70 (5.7%)
6-11 Years: BD mRNA-1273 25 μg0/2,766 (0%)12/2,766 (0.4%)468/2,766 (16.9%)
6-11 Yrs: BD mRNA-1273.214 25 μg0/184 (0%)0/184 (0%)28/184 (15.2%)
6 Months-5 Yrs: BD mRNA-1273 10 μg0/212 (0%)1/212 (0.5%)56/212 (26.4%)
6 Months-5 Yrs: BD mRNA-1273 25 μg0/89 (0%)1/89 (1.1%)20/89 (22.5%)
6 Months-5 Yrs: BD mRNA-1273.214 10 μg1/2,771 (0%)23/2,771 (0.8%)655/2,771 (23.6%)
6 Months-5 Yrs: BD mRNA-1273.214 25 μg0/28 (0%)0/28 (0%)4/28 (14.3%)
Most frequent serious events
Showing 10 of 114
Most frequent serious events
EventPart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µgPart 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg (Crossover)Part 2 (2-5 Years): PS PBO - mRNA-1273 25 μg (Crossover)Part 2 (6-23 Months): PBO - mRNA-1273 25 μg (Crossover)Part 3 (6-11 Years): BD mRNA-1273 25 µg6-11 Years: BD mRNA-1273 25 μg6-11 Yrs: BD mRNA-1273.214 25 μg6 Months-5 Yrs: BD mRNA-1273 10 μg6 Months-5 Yrs: BD mRNA-1273 25 μg6 Months-5 Yrs: BD mRNA-1273.214 10 μg6 Months-5 Yrs: BD mRNA-1273.214 25 μg
ConstipationGastrointestinal disorders0/3801/3710/690/1550/1500/9950/30070/10071/30310/6660/19940/900/7010/6400/4440/700/27660/1840/2121/890/27710/28
BronchospasmRespiratory, thoracic and mediastinal disorders0/3800/3710/690/1550/1500/9950/30070/10070/30310/6661/19941/900/7010/6400/4440/700/27660/1840/2120/890/27710/28
Anaphylactic reactionImmune system disorders0/3800/3710/690/1551/1500/9950/30070/10070/30310/6660/19940/900/7010/6400/4440/700/27660/1840/2120/890/27710/28
Rhinovirus infectionInfections and infestations0/3800/3710/690/1551/1500/9950/30071/10072/30311/6663/19940/900/7010/6400/4440/702/27660/1840/2120/890/27710/28
Febrile convulsionNervous system disorders0/3800/3710/690/1551/1500/9950/30070/10070/30310/6663/19940/900/7011/6400/4440/701/27660/1840/2120/890/27710/28
BronchiolitisInfections and infestations0/3800/3710/690/1550/1500/9950/30070/10071/30314/6668/19940/900/7011/6401/4440/700/27660/1840/2120/892/27710/28
AppendicitisInfections and infestations2/3800/3710/690/1550/1500/9954/30070/10070/30310/6660/19940/901/7010/6400/4440/702/27660/1840/2120/890/27710/28
Pharyngeal abscessInfections and infestations0/3800/3710/690/1550/1500/9950/30070/10070/30310/6660/19940/900/7010/6400/4440/700/27660/1841/2120/890/27710/28
Streptococcal infectionInfections and infestations0/3800/3710/690/1550/1500/9950/30070/10070/30310/6660/19940/900/7010/6400/4440/700/27660/1841/2120/890/27710/28
Respiratory syncytial virus infectionInfections and infestations0/3800/3710/690/1550/1500/9950/30070/10072/30310/6663/19940/900/7012/6400/4440/700/27660/1840/2120/892/27710/28
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPart 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µgPart 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg (Crossover)Part 2 (2-5 Years): PS PBO - mRNA-1273 25 μg (Crossover)Part 2 (6-23 Months): PBO - mRNA-1273 25 μg (Crossover)Part 3 (6-11 Years): BD mRNA-1273 25 µg6-11 Years: BD mRNA-1273 25 μg6-11 Yrs: BD mRNA-1273.214 25 μg6 Months-5 Yrs: BD mRNA-1273 10 μg6 Months-5 Yrs: BD mRNA-1273 25 μg6 Months-5 Yrs: BD mRNA-1273.214 10 μg6 Months-5 Yrs: BD mRNA-1273.214 25 μg
Upper respiratory tract infectionInfections and infestations56/38050/3719/6945/15537/15047/995284/3007190/1007630/3031146/666512/19949/9059/70139/64031/4444/70164/27662/18424/2126/89132/27710/28
PyrexiaGeneral disorders17/38021/3712/6923/15540/15010/99583/300749/1007222/303157/666194/19940/900/7010/6400/4440/700/27660/1840/2120/890/27710/28
RhinorrhoeaRespiratory, thoracic and mediastinal disorders12/38026/3716/6913/15534/15028/995107/300770/1007250/303153/666173/19940/900/7010/6400/4440/700/27660/1840/2120/890/27710/28
CoughRespiratory, thoracic and mediastinal disorders23/38034/3718/6912/15527/15026/995136/300769/1007262/303143/666130/19940/900/7010/6400/4440/700/27660/1840/2120/890/27710/28
Otitis mediaInfections and infestations5/3801/3713/697/15524/1502/99531/300742/1007231/303154/666258/19940/905/70123/64038/4440/7046/27661/18416/2125/89225/27711/28
Ear infectionInfections and infestations1/3809/3714/693/15519/1503/99522/300747/1007237/303164/666249/19940/900/7010/6400/4440/7037/27662/18410/2123/89141/27712/28
Nasal congestionRespiratory, thoracic and mediastinal disorders27/38034/3715/695/15518/1500/9950/30070/10070/30310/6660/19940/900/7010/6400/4440/700/27660/1840/2120/890/27710/28
TeethingGastrointestinal disorders0/3800/3710/690/15515/1500/9951/30077/10079/303139/666109/19940/900/7010/6400/4440/700/27660/1840/2120/890/27710/28
Otitis media acuteInfections and infestations0/3803/3711/692/15515/1501/99512/300716/100784/303118/666113/19940/900/7010/6400/4440/700/27660/1840/2120/890/27710/28
InfluenzaInfections and infestations0/3800/3710/690/1550/1500/9950/30070/10070/30310/6660/19940/900/7010/6400/4440/70132/276618/1846/2123/89102/27711/28

Baseline characteristics

Safety Set of Part 1 and Part 3 included all dosed participants and of Part 2 included all randomized participants who received any study injection. Study mRNA-1273-P301 (P301) (NCT04470427) mRNA-1273 100 μg: PPIS of randomly selected participants from study P301 aged 18-25 meeting pre-specified criteria.

Age, Customized
Age, Customized(Participants)Part 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μgTotal
Age Categorical Data for Participants Enrolled in Study mRNA-1273-P204 — Infants and toddlers (28 days - 23 months)00001500011186691989002837
Age Categorical Data for Participants Enrolled in Study mRNA-1273-P204 — Children (2 - 11 years)380371751490100430119973022069009105
Age Categorical Data for Participants Enrolled in Study mRNA-1273-P204 — Adults (between 18 and 64 years)00000000000000
Age Categorical Data for Participants Enrolled in Study mRNA-1273-P301 — Infants and toddlers (28 days - 23 months)00000000000000
Age Categorical Data for Participants Enrolled in Study mRNA-1273-P301 — Children (2 - 11 years)00000000000000
Age Categorical Data for Participants Enrolled in Study mRNA-1273-P301 — Adults (between 18 and 64 years)000000000000296296
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μgTotal
Sex Data for Participants Enrolled in Study mRNA-1273-P204 — Female185199396967516145649814903419813405875
Sex Data for Participants Enrolled in Study mRNA-1273-P204 — Male1951723680834881555510155032810145606067
Sex Data for Participants Enrolled in Study mRNA-1273-P301 — Female000000000000153153
Sex Data for Participants Enrolled in Study mRNA-1273-P301 — Male000000000000143143
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μgTotal
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P204 — Hispanic or Latino7269241715183562142429942572901893
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P204 — Not Hispanic or Latino304296511291338112421857259356817195809940
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P204 — Unknown or Not Reported46032102891871930109
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Hispanic or Latino0000000000007878
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Not Hispanic or Latino000000000000216216
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Unknown or Not Reported00000000000022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1 (6-11 Years): mRNA-1273 50 µgPart 1 (6-11 Years): mRNA-1273 100 µgPart 1 (2-5 Years): mRNA-1273 25 µgPart 1 (2-5 Years): mRNA-1273 50 µgPart 1 (6-23 Months): mRNA-1273 25 µgPart 2 (6-11 Years): PlaceboPart 2 (6-11 Years): mRNA-1273 50 µgPart 2 (2-5 Years): PlaceboPart 2 (2-5 Years): mRNA-1273 25 µgPart 2 (6-23 Months): PlaceboPart 2 (6-23 Months): mRNA-1273 25 µgPart 3 (6-11 Years): Primary Series mRNA-1273 25 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μgTotal
Race Data for Participants Enrolled in Study mRNA-1273-P204 — White266284541281246761960793230752715684808735
Race Data for Participants Enrolled in Study mRNA-1273-P204 — Black or African American341337394310381421862370761
Race Data for Participants Enrolled in Study mRNA-1273-P204 — Asian282583710029751191389420844
Race Data for Participants Enrolled in Study mRNA-1273-P204 — American Indian or Alaska Native02001315311072044
Race Data for Participants Enrolled in Study mRNA-1273-P204 — Native Hawaiian or Other Pacific Islander100000435000013
Race Data for Participants Enrolled in Study mRNA-1273-P204 — Other3107132262164373300207
Race Data for Participants Enrolled in Study mRNA-1273-P204 — Multiple3931310119833010032476215001237
Race Data for Participants Enrolled in Study mRNA-1273-P204 — Not Reported9400010234132111077
Race Data for Participants Enrolled in Study mRNA-1273-P204 — Unknown0200111004150024
Race Data for Participants Enrolled in Study mRNA-1273-P301 — White000000000000207207
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Black or African American0000000000002929
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Asian0000000000003030
Race Data for Participants Enrolled in Study mRNA-1273-P301 — American Indian or Alaska Native00000000000033
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Native Hawaiian or Other Pacific Islander00000000000022
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Other00000000000088
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Multiple0000000000001414
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Not Reported00000000000033
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Unknown00000000000000
09

Study locations

91 sites
  • Children's of Alabama
    Birmingham, Alabama 35233-1711, United States
  • MedPharmics, LLC
    Phoenix, Arizona 85015-1105, United States
  • Emmaus Research Center Inc
    Anaheim, California 92804-1866, United States
  • Velocity Clinical Research - Banning - ERN- PPDS
    Banning, California 92220-3082, United States
  • SeraCollection Research Services LLC
    El Monte, California 91731, United States
  • UCSD Altman Clinical and Translational Research Institute Building
    La Jolla, California 92037, United States
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
  • Center for Clinical Trials, LLC
    Paramount, California 90723-5459, United States
  • Rady Childrens Hospital San Diego - PIN
    San Diego, California 92123, United States
  • Carey Chronis MD Pediatric, Infant and Adolescent Medicine - FOMAT
    Ventura, California 93003-5369, United States
  • Children's Hospital Colorado - (CRS)
    Aurora, Colorado 80045-7144, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06519-1712, United States
  • Prohealth Research Center
    Doral, Florida 33166, United States
  • University of Florida Jacksonville
    Jacksonville, Florida 32209-6511, United States
  • Kissimmee Clinical Research (KCR)
    Kissimmee, Florida 34743, United States
  • Allied Biomedical Research Institute
    Miami, Florida 33155-4630, United States
  • Pensacola Research Consultants Inc. d/b/a Avanza Medical Research Center
    Pensacola, Florida 32503, United States
  • University of South Florida
    Tampa, Florida 33613-3946, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322-1014, United States
  • Iresearch Atlanta, LLC
    Decatur, Georgia 30030-3438, United States
  • iresearch Savannah
    Savannah, Georgia 31405, United States
  • Velocity Clinical Research - Boise - ERN - PPDS
    Meridian, Idaho 83642-6246, United States
  • Ann and Robert H Lurie Childrens Hospital of Chicago
    Chicago, Illinois 60611-2991, United States
  • Alliance for Multispecialty Research -El Dorado
    El Dorado, Kansas 67042-2187, United States
  • University of Kentucky
    Lexington, Kentucky 40504-3516, United States
  • Michael W Simon, MD PSC
    Lexington, Kentucky 40517-8366, United States
  • Our Lady of the Lake Regional Medical Center
    Baton Rouge, Louisiana 70809, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70809, United States
  • MedPharmics - Platinum
    Metairie, Louisiana 70006-4152, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201-1519, United States
  • Javara Inc.
    Chevy Chase, Maryland 20815, United States
  • The Pediatric Centre of Frederick
    Frederick, Maryland 21702-4747, United States
  • Tufts University - Boston - PPDS
    Boston, Massachusetts 02111-1552, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114-2621, United States
  • Pediatric Associates of Fall River
    Fall River, Massachusetts 02721-1778, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • Henry Ford Health System
    Detroit, Michigan 48202-2608, United States
  • Clinical Research Institute, Inc - CRN - PPDS
    Minneapolis, Minnesota 55402-2700, United States
  • University of Minnesota Masonic Children's Hospital
    Minneapolis, Minnesota 55454, United States
  • MediSync Clinical Research Hattiesburg Clinic
    Petal, Mississippi 39465, United States
  • University of Missouri Health Care System
    Columbia, Missouri 65212-1000, United States
  • Washington University in St. Louis
    Saint Louis, Missouri 63110-1010, United States
  • Meridian Clinical Research (Hastings, Nebraska)
    Hastings, Nebraska 68901, United States
  • Meridian Clinical Research (Norfolk-Nebraska) - Platinum - PPDS
    Norfolk, Nebraska 68701-2669, United States
  • Quality Clinical Research - PPDS
    Omaha, Nebraska 68114-3723, United States
  • MedPharmics, LLC
    Albuquerque, New Mexico 87102, United States
  • University of New Mexico
    Albuquerque, New Mexico 87106-2719, United States
  • Meridian Clinical Research (Endwell-New York) - Platinum - PPDS
    Binghamton, New York 13901-1046, United States
  • Certified Research Associates
    Cortland, New York 13045-9398, United States
  • Child Healthcare Associates - East Syracuse
    East Syracuse, New York 13057, United States
  • University of Rochester Medical Center
    Rochester, New York 14642-0001, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794-0001, United States
  • OnSite Clinical Solutions, LLC
    Charlotte, North Carolina 28208, United States
  • Javara Inc. - Winston-Salem
    Winston-Salem, North Carolina 27101-4263, United States
  • Cincinnati Children's Hospital Medical Center - PIN
    Cincinnati, Ohio 45229-3026, United States
  • Lynn Health Science Institute - ERN - PPDS
    Oklahoma City, Oklahoma 73112-4703, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104-4319, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15213-1481, United States
  • Velocity Clinical Research - Providence - ERN - PPDS
    Warwick, Rhode Island 02886-1617, United States
  • Coastal Pediatric Associates
    Charleston, South Carolina 29414-5834, United States
  • Medical University of South Carolina- PPDS
    Charleston, South Carolina 29425-8903, United States
  • Palmetto Pediatrics
    North Charleston, South Carolina 29406-9170, United States
  • Meharry Medical College - Clinical and Translational Research Center & Meharry Medical College - Pediatric Department
    Nashville, Tennessee 37208-3501, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-0011, United States
  • Tekton Research - Texas - Platinum - PPDS
    Austin, Texas 78745, United States
  • BRCR Global Texas
    Edinburg, Texas 78539-8462, United States
  • Pininos Pediatric Services
    El Paso, Texas 79902-1139, United States
  • Ventavia Research Group - Platinum - PPDS
    Houston, Texas 77008-1398, United States
  • Baylor College of Medicine
    Houston, Texas 77030-3411, United States
  • West Houston Clinical Research - Hunt
    Houston, Texas 77055-1626, United States
  • Texas Center for Drug Development, Inc
    Houston, Texas 77081, United States
  • Cyfair Clinical Research Center - ERN- PPDS
    Houston, Texas 77375-6579, United States
  • Village Health Partners - HUNT
    Plano, Texas 75024, United States
  • Victoria Clinical Research
    Port Lavaca, Texas 77901-5531, United States
  • Javara, Inc.
    The Woodlands, Texas 77382, United States
  • Crossroads Clinical Research (Victoria)
    Victoria, Texas 77901, United States
  • Tanner Clinic
    Layton, Utah 84041, United States
  • Advanced Clinical Research/Velocity Clinical Research
    West Jordan, Utah 84088, United States
  • PI-Coor Clinical Research, LLC
    Burke, Virginia 22015-1635, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23226, United States
  • University of Wisconsin - Madison
    Madison, Wisconsin 53792-0001, United States
  • University of Calgary
    Calgary, Alberta T3B 6A8, Canada
  • Children's and Women's Health Centre of British Columbia
    Vancouver, British Columbia V5Z 4H4, Canada
  • Winnipeg Children's Hospital, HSC-Winnipeg
    Winnipeg, Manitoba R3E 3P4, Canada
  • Dalhousie University
    Halifax, Nova Scotia B3H 1, Canada
  • Childrens Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • The Hospital for Sick Children (SickKids)
    Toronto, Ontario M5G 1X8, Canada
  • Dr. Anil K. Gupta Medicine Professional Corporation - Clinic/Outpatient Facility
    Toronto, Ontario M9V 4B4, Canada
  • McGill University Health Centre-Vaccine Study Centre
    Pierrefonds, Quebec H9H 4Y6, Canada
10

References and documents

Publications

  • Anderson EJ, Creech CB, Berthaud V, Piramzadian A, Johnson KA, Zervos M, Garner F, Griffin C, Palanpurwala K, Turner M, Gerber J, Bennett RL, Ali K, Ampajwala M, Berman G, Nayak J, Chronis C, Rizzardi B, Muller WJ, Smith CA, Fuchs G, Hsia D, Tomassini JE, DeLucia D, Reuter C, Kuter B, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, McPhee R, Pajon R, Aunins A, Das R, Miller JM, Schnyder Ghamloush S; KidCOVE Study Group. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. N Engl J Med. 2022 Nov 3;387(18):1673-1687. doi: 10.1056/NEJMoa2209367. Epub 2022 Oct 19. PubMed 36260859 ↗
  • Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, Finkelstein D, Pickrell P, Kirstein J, Yut C, Blair R, Clifford RA, Dunn M, Campbell JD, Montefiori DC, Tomassini JE, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, McPhee R, Pajon R, Das R, Miller JM, Schnyder Ghamloush S; KidCOVE Study Group. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N Engl J Med. 2022 May 26;386(21):2011-2023. doi: 10.1056/NEJMoa2203315. Epub 2022 May 11. PubMed 35544369 ↗
  • Lynch LR, Clifford H, Ko R, Hache M, Sun W. Primer of COVID-19 Vaccines for the Perioperative Physician. J Neurosurg Anesthesiol. 2022 Jan 1;34(1):101-106. doi: 10.1097/ANA.0000000000000802. PubMed 34870630 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Mar 2024, 36 months.

Results were first posted in Jun 2025, 1 year 2 months after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 36 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 15, 2021
StartActual
Mar 15, 2021
Primary completionActual
Mar 15, 2024
CompletionActual
Mar 15, 2024
Results first posted
Jun 13, 2025
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04796896
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Mar 15, 2021
Primary completion
Mar 15, 2024
Completion
Mar 15, 2024
Results posted
Jun 13, 2025
Last update
Jun 13, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273

Start the discussion